As of the cutoff date, June 25, 2024, 39 patients have been enrolled in the ongoing Phase 1 clinical trial across five dose levels of ELVN-001, ranging from 10 mg once daily (QD) to 120 mg QD, and the ...

Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $1.9 million, or ...

The Proposed Transaction is planned to be completed by way of a three-cornered merger pursuant to which, a wholly owned subsidiary of the Company incorporated in Nevada will merge with 3Win and 3Win ...

OTTAWA, Ontario, Sept. 28, 2024 (GLOBE NEWSWIRE) -- As the world observes International Safe Abortion Day, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is reaffirming its ...

The company expects to submit the new 510 (k) application in the coming quarter and will provide updates on its progress in the regulatory process, as appropriate.

Webcast to be held Monday, September 23, at 8:00 a.m. ET ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced ...

“We have seen the profound impact this medicine has had for GA patients in the U.S. and remain committed to expanding access to this crucial treatment, focusing on serving unmet patient needs in the U ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA; Represents the second EMA approval of an MVA-BN-based vaccine ...

We’re thrilled to unite the strengths of DUB Enterprises and Leap Surgical into a single, powerful entity. This acquisition enables us to provide top-tier service and access to high-quality medical ...

This new European approval reinforces Ipsen’s commitment to advancing medical innovations to treat people living with rare cholestatic liver diseases ...

Pending authorization of the Omicron KP.2-adapted vaccine by the EC, both the Omicron KP.2-adapted vaccine and the Omicron JN.1-adapted vaccine will be available across the EU, though availability ...